MARKET

KLRS

KLRS

Kalaris Therapeutics Inc
NASDAQ
3.275
+0.025
+0.76%
Opening 10:48 05/20 EDT
OPEN
3.210
PREV CLOSE
3.250
HIGH
3.440
LOW
3.210
VOLUME
7.85K
TURNOVER
--
52 WEEK HIGH
24.15
52 WEEK LOW
3.100
MARKET CAP
61.25M
P/E (TTM)
-0.5248
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at KLRS last week (0512-0516)?
Weekly Report · 1d ago
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 4d ago
Why Quantum Computing Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Benzinga · 4d ago
Buy Rating for Kalaris Therapeutics: Promising TH103 Development and Strong Financial Position
TipRanks · 5d ago
Kalaris Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Reuters · 6d ago
Kalaris Therapeutics, Inc. reports Q1 results
Seeking Alpha · 6d ago
Kalaris Therapeutics Q1 EPS $(2.52) Misses $(1.17) Estimate
Benzinga · 6d ago
Kalaris Therapeutics reports Q1 EPS ($2.52) vs ($2.60) last year
TipRanks · 6d ago
More
About KLRS
Kalaris Therapeutics, Inc., formerly AlloVir, Inc., is a clinical-stage biopharmaceutical company engaged in the development and commercialization of treatments for prevalent retinal diseases. The Company is focused on the development of TH103, a differentiated anti-vascular endothelial growth factor (VEGF) investigational therapy. TH103 is a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor and has been specifically engineered for potentially improved VEGF inhibition and longer retention in the retina. TH103 is being evaluated in an ongoing, Phase I clinical trial for the treatment of neovascular age-related macular degeneration (nAMD), with plans to develop TH103 for additional neovascular and exudative diseases of the retina such as diabetic macular edema (DME), and retinal vein occlusion (RVO).

Webull offers Kalaris Therapeutics Inc stock information, including NASDAQ: KLRS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KLRS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KLRS stock methods without spending real money on the virtual paper trading platform.